Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211425 | 0.86 | L3MBTL1 (0.39) | HDAC1HDAC2LMNANPSR1CNR1 | |
| SCHEMBL7095476 | 0.85 | CNR1 (0.42) | HDAC1HDAC2LMNANPSR1CNR1 | |
| SCHEMBL5769433 | 0.85 | PTPN1 (0.53) | PTPN1PTPN2HDAC1HDAC2LMNA | |
| SCHEMBL5770569 | 0.85 | PTPN1 (0.53) | PTPN1PTPN2HDAC1HDAC2LMNA | |
| SCHEMBL5770319 | 0.76 | CHRM1 (0.47) | KLKB1 | |
| SCHEMBL5771236 | 0.76 | CHRM1 (0.39) | — | |
| SCHEMBL5769066 | 0.72 | PTPN1 (0.39) | PTPN1HDAC1HDAC2LMNANPSR1 | |
| SCHEMBL5837772 | 0.71 | PTPN1 (0.47) | PTPN1PTPN2L3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL5768831 | 0.70 | CHRM1 (0.41) | KLKB1 | |
| SCHEMBL5837796 | 0.70 | PTPN1 (0.46) | PTPN1PTPN2HDAC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301516-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-6613903-B2 | Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | PTPRO, PTPN1, PTPRS | PTPN1 2/4885PTPN2 12/4885HDAC1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.